On July 10, 2026, the company received a Nasdaq Staff Determination Letter stating it is not in compliance with Listing Rule 5550(a)(2) after its bid price stayed below $1.00 for 30 consecutive business days. Due to a reverse split effected on August 12, 2025, it is not eligible for the standard 180-day cure period; the company will request a hearing, which will stay any suspension or delisting action pending a decision.
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.